FCFS

157.61

-2.32%↓

RPT.US

2.53

-0.39%↓

FCFS

157.61

-2.32%↓

RPT.US

2.53

-0.39%↓

FCFS

157.61

-2.32%↓

RPT.US

2.53

-0.39%↓

FCFS

157.61

-2.32%↓

RPT.US

2.53

-0.39%↓

FCFS

157.61

-2.32%↓

RPT.US

2.53

-0.39%↓

Search

Sartorius Stedim Biotech.

Atidarymo kaina

SektoriusFinansų sektorius

190.2 -3.21

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

189.25

Max

195.95

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-23M

93M

Pardavimai

400K

745M

P/E

Sektoriaus vid.

69.078

31.165

Pelnas, tenkantis vienai akcijai

0.94

Pelno marža

12.43

Darbuotojai

10,134

EBITDA

-55M

201M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+17.82% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

174M

20B

Ankstesnė atidarymo kaina

193.41

Ankstesnė uždarymo kaina

190.2

Naujienos nuotaikos

By Acuity

44%

56%

186 / 528 reitingas Finance

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Sartorius Stedim Biotech. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-11-13 21:34; UTC

Uždarbis

Applied Materials 4Q Sales Fall; Forecasts Higher Demand in 2H26

2025-11-13 23:45; UTC

Rinkos pokalbiai

Nikkei May Fall After Wall Street's Weakness -- Market Talk

2025-11-13 23:42; UTC

Įsigijimai, susijungimai, perėmimai

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 4th Update

2025-11-13 23:41; UTC

Rinkos pokalbiai

Gold Edges Higher on Possible Dip-Buying -- Market Talk

2025-11-13 23:24; UTC

Uždarbis

JBS NV: Robust U.S. Beef Demand Supported 3Q North America Sales >JBS

2025-11-13 23:24; UTC

Uždarbis

JBS NV: Live Cattle Prices Have Remained High, Pressuring Profitability >JBS

2025-11-13 23:23; UTC

Uždarbis

JBS NV 3Q EPS 52c >JBS

2025-11-13 23:23; UTC

Uždarbis

JBS NV 3Q Sales $22.6B >JBS

2025-11-13 23:04; UTC

Rinkos pokalbiai

RBA Looks Set To Remain Sidelined For a While Yet -- Market Talk

2025-11-13 22:02; UTC

Uždarbis

Nu Holdings 3Q Net $783M >NU

2025-11-13 22:01; UTC

Uždarbis

Nu Holdings 3Q Rev $4.2B >NU

2025-11-13 21:51; UTC

Įsigijimai, susijungimai, perėmimai

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 3rd Update

2025-11-13 21:50; UTC

Uždarbis

Disney Posts Roughly Flat Quarterly Revenue as TV Declines Continue -- 4th Update

2025-11-13 21:45; UTC

Įsigijimai, susijungimai, perėmimai

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 2nd Update

2025-11-13 21:41; UTC

Įsigijimai, susijungimai, perėmimai

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- Update

2025-11-13 21:36; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Plans to Bid for All of Warner Bros., Sources Say -- WSJ

2025-11-13 21:36; UTC

Įsigijimai, susijungimai, perėmimai

Paramount, Comcast, Netflix Among Potential Bidders That Have Looked at Warner Bros. Financials, Sources Say -- WSJ

2025-11-13 21:36; UTC

Įsigijimai, susijungimai, perėmimai

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- WSJ

2025-11-13 21:36; UTC

Įsigijimai, susijungimai, perėmimai

Netflix, Comcast Each Considering Pursuing Warner Bros. Studio, Streaming Assets, Sources Say -- WSJ

2025-11-13 21:36; UTC

Įsigijimai, susijungimai, perėmimai

Bids for Warner Bros. Discovery Due Next Week, Sources Say -- WSJ

2025-11-13 21:33; UTC

Rinkos pokalbiai

Banks See CAD Appreciation Through 2026, Trade Poses 'Clear' Risk -- Market Talk

2025-11-13 21:33; UTC

Uždarbis

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares -- Barrons.com

2025-11-13 21:31; UTC

Uždarbis

Applied Materials Stock Falls Despite Strong Earnings -- Barrons.com

2025-11-13 21:25; UTC

Uždarbis

Figure Tech Solutions 3Q Rev $156.4M >FIGR

2025-11-13 21:25; UTC

Uždarbis

Figure Tech Solutions 3Q EPS 34c >FIGR

2025-11-13 21:23; UTC

Uždarbis

Intchains Group 3Q Rev $1.3M >ICG

2025-11-13 21:03; UTC

Uždarbis

Applied Materials Sees 1Q Rev $6.35B-$7.35B >AMAT

2025-11-13 21:02; UTC

Uždarbis

Applied Materials Sees 1Q Adj EPS $1.98-Adj EPS $2.38 >AMAT

2025-11-13 21:01; UTC

Uždarbis

Applied Materials 4Q Rev $6.8B >AMAT

2025-11-13 21:01; UTC

Uždarbis

Applied Materials 4Q Gross Margin 48.0% >AMAT

Akcijų palyginimas

Kainos pokytis

Sartorius Stedim Biotech. Prognozė

Kainos tikslas

By TipRanks

17.82% į viršų

12 mėnesių prognozė

Vidutinis 228.57 EUR  17.82%

Aukščiausias 246 EUR

Žemiausias 210 EUR

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sartorius Stedim Biotech. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

7 ratings

5

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

202.7 / 211.7Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Strong Bullish Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Rinkos nuotaikos

By Acuity

186 / 528 reitingas Finansų sektorius

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
help-icon Live chat